The bill requires the Secretary of Health and Human Services, working with Commerce, CMS’s Council for Technology and Innovation, and the FDA Commissioner, to run a program that facilitates and coordinates U.S.–Israel collaboration on developing and delivering health care products and services. It enumerates a broad menu of activities—from joint research and clinical trials to telemedicine, data sharing, and joint biological-product manufacturing—and authorizes federal funding for implementation.
Why it matters: the measure packages diplomatic, regulatory, and industrial policy tools into a single program aimed at accelerating commercialization, harmonizing regulation, and strengthening supply chains with an allied partner. For compliance officers and in-house counsels this bill signals potential cross-border data-sharing arrangements, IP coordination efforts, and new incentives for U.S. firms to enter Israeli markets (and vice versa), all under a Federally coordinated program.
At a Glance
What It Does
The bill directs HHS to create and run a program to facilitate and coordinate collaboration between U.S. and Israeli entities on health care product development and delivery, including R&D, regulatory alignment, manufacturing, telemedicine, and disease prevention. It lists specific program components and authorizes funding for a multi-year period.
Who It Affects
Biotechnology and medical device companies, start‑ups seeking market access, hospitals and health systems pursuing telehealth interoperability, FDA and other federal agencies tasked with regulatory cooperation, and institutions involved in joint manufacturing or clinical trials.
Why It Matters
This consolidates multiple levers—funding, regulatory cooperation, and public‑private partnership authority—into a focused U.S.–Israel health collaboration effort, potentially lowering barriers to cross‑border commercialization while creating new compliance and IP coordination obligations for private-sector participants.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a federally led program, to be run by HHS in consultation with Commerce, the CMS Council for Technology and Innovation, and the FDA Commissioner, to foster closer collaboration between U.S. and Israeli actors in health care technologies. Rather than funding discrete grants alone, it prescribes a suite of activities: joint research projects and early‑stage clinical trial support; mechanisms to help startups commercialize technologies across the two markets; and efforts to improve telemedicine interoperability and digital health cooperation.
On the regulatory side, the statute calls for joint work on intellectual property protection, regulatory data protection for biologics, and incentivizing regulatory harmonization—including encouragement of mutual recognition for pharmaceutical Good Manufacturing Practices and expanded use of Project Orbis for oncology reviews. The bill also pushes for a framework to share health data for research with Israel’s Ministry of Health and emphasizes cybersecurity and patient‑privacy standards when exchanging information.The bill singles out biological product manufacturing as a priority: it encourages joint manufacturing facilities located in the United States, workforce training and exchange programs, public‑private partnerships to scale manufacturing, and planning to bolster supply‑chain resilience.
HHS may establish a physical U.S.–Israel Health Care Collaboration Center to coordinate these efforts, and the statute directs HHS to begin implementation within six months of enactment. The text ties activity to appropriations and authorizes federal funding across several fiscal years.
The Five Things You Need to Know
The bill authorizes $8,000,000 per year for each of fiscal years 2026 through 2030 to carry out the program.
HHS must commence implementation not later than six months after enactment.
The statute requires HHS to consult with the Secretary of Commerce, the CMS Council for Technology and Innovation, and the FDA Commissioner when carrying out the program.
The bill authorizes HHS to establish a joint United States‑Israel Health Care Collaboration Center located in the United States to coordinate research, commercialization, and manufacturing activities.
The program explicitly encourages regulatory harmonization measures, including potential mutual recognition for pharmaceutical Good Manufacturing Practices and expanded participation in Project Orbis for concurrent oncology product reviews.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Declares the act’s formal short names: the Maximizing Israel‑U.S. Research Advancement and Collaborative Leadership in Emerging Medical Technology Act of 2025 and the MIRACLE Medical Technology Act of 2025. This is a naming provision only and does not change program substance.
Program establishment and agency consultations
Directs the Secretary of HHS to carry out a program to facilitate and coordinate U.S.–Israel efforts on health care product development and delivery, explicitly requiring consultation with Commerce, the CMS Council for Technology and Innovation, and the FDA Commissioner. Practically, this centralizes leadership at HHS while building in cross‑agency input—meaning implementation choices (grants, MOUs, centers) will flow through HHS.
Joint R&D, trials, and data‑sharing framework
Specifies joint research projects, a focus on medical devices, biologics, genomics, and early‑stage clinical trials, plus direction to work toward a framework for sharing health data with Israel’s Ministry of Health. This provision opens the door to cross‑border clinical collaboration and shared research databases, which will require legal and privacy risk assessments and possibly new contractual templates for data use and transfer.
IP protection, regulatory data protection, and Project Orbis expansion
Directs joint efforts to ensure intellectual property protection, increase regulatory harmonization (including data protection for biologics), encourage GMP mutual recognition dialogues, and expand Project Orbis participation. These are framing directives rather than binding treaty commitments; they instruct agencies to pursue cooperative agreements, which can change how private parties approach filings and manufacturing strategies in each market.
Joint biological‑product manufacturing and optional center
Encourages U.S.-based joint manufacturing facilities, workforce training, supply‑chain resilience planning, and public‑private partnerships; separately, authorizes HHS to establish a U.S.–Israel Health Care Collaboration Center. The manufacturing language supports nearshore production and training pipelines but leaves specifics—site selection, partners, procurement rules—to later implementation decisions, while the center creates a potential physical coordination point.
Timing and funding
Requires HHS to start implementation within six months of enactment and authorizes appropriations of $8 million per year for fiscal years 2026–2030. The statute conditions program activity on the availability of appropriations, so operational scale will depend on future budget decisions and agency priorities.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- U.S. and Israeli biotech and medical device startups — the bill encourages joint projects, market‑entry support, and technology transfer mechanisms that can shorten commercialization timelines and broaden market access.
- Hospitals and health systems pursuing telemedicine — the program’s focus on interoperability and digital‑health cooperation can reduce technical barriers to cross‑border telehealth services and joint care models.
- U.S. biological‑product manufacturers and workforce — the emphasis on joint manufacturing facilities, training, and scale‑up incentives supports capacity building and potentially creates new manufacturing jobs domestically.
- Oncology developers — the push to expand Project Orbis participation for concurrent submission and review can speed access to multinational regulatory reviews, particularly for cancer products.
Who Bears the Cost
- HHS and partner federal agencies — they must stand up and manage the program, negotiate agreements, and absorb staffing and coordination costs beyond the modest authorization.
- U.S. taxpayers — the bill authorizes $8 million annually but actual costs may rise if agencies scale the program or deploy additional resources, and funding remains subject to appropriation.
- Private firms engaging in cross‑border collaborations — companies will face legal, compliance, and IP‑management costs to participate in data‑sharing, harmonization efforts, or joint manufacturing ventures.
- Hospitals and health systems — meeting interoperability, cybersecurity, and cross‑border privacy standards may require new IT investments and contractual safeguards, especially where patient data crosses jurisdictions.
Key Issues
The Core Tension
The bill trades off speed and scale of cross‑border medical innovation against the need to protect patient data, intellectual property, and domestic supply‑chain control: accelerating joint R&D and manufacturing with an allied partner can lower costs and speed access to therapies, but it raises real questions about data privacy, IP governance, and how much control the United States cedes in synchronized regulatory or manufacturing arrangements.
The bill sets a broad agenda but leaves critical design choices to agency rulemaking, interagency agreements, and future appropriations. The authorized funding—$8 million per year—is modest relative to the program’s span (R&D support, manufacturing facilities, workforce exchanges, regulatory workstreams), so implementation will likely prioritize low‑cost coordination activities (MOUs, pilot projects) unless Congress allocates more funds.
Agencies will need to develop legal frameworks for cross‑border health data sharing that reconcile HIPAA, U.S. export controls, Israeli privacy law, and cybersecurity requirements; that work can be time‑consuming and legally fraught.
On intellectual property and technology transfer, the statute directs protection and harmonization efforts while also encouraging technology transfer and joint manufacturing—two goals that can conflict. Private firms may demand strong contractual protections or delay sharing core know‑how.
Similarly, encouraging mutual recognition of GMP or expedited regulatory pathways depends on deep technical alignment between agencies; the bill instructs agencies to pursue these paths but does not grant them new statutory authorities to bind private sector or foreign regulators, leaving outcomes uncertain.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.